MedAssets Inc.

Oppenheimer has published a report on MedAssets Inc (NASDAQ: MDAS) reviewing the second quarter and lowering the PT from $21 to $20. In the report, Oppenheimer wrote, "MedAssets reported better than expected results, primarily on the early recognitionof RCM incentive fees. As has been widely...

According to Oppenheimer, MedAssets (NASDAQ: MDAS) announced that its agreement with the Texas Purchasing Coalition has been amended to include Hendrick Health System. Oppenheimer said that normally, it would not comment on the inclusion of an additional hospital to a GPO contract. “However, given...

According to Piper Jaffray, MedAssets (NASDAQ: MDAS) price target is lowered. Piper Jaffray said that has announced the resignation of Pat Ryan, President of the Spend Management Division, Board Member, and former CEO of Broadlane. “On the one hand, this is not new news because management hinted as...

Piper Jaffray has lowered the price target on MedAssets (NASDAQ: MDAS) from $15 to $11 and maintains its Underweight rating.

Bank of America is maintaining its Buy rating and its $21 price target on MedAssets Inc. (NASDAQ: MDAS) despite recent dips in share price for the company. In the report, Bank of America states, “MDAS' shares are off 8% over the past two weeks, underperforming a weak S&P 500 (-1%) on...

BMC Drops Coverage of MedAssets (MDAS) BMC has dropped its coverage of MedAssets (NASDAQ: MDAS). Shares of BMC closed Monday at $15.09, down 0.25% from Friday's close.

Citi Comments On MedAssets' Q4 Results In a report published by Citi, MedAssets (NASDAQ: MDAS) reported its Q4 results and 2011 guidance shortfall. Citi said that it had the opportunity to host a dinner with MDAS management and the company participated in our annual Global Healthcare Conference...

According to Morgan Keegan, MedAssets (NASDAQ: MDAS) should strongly consider taking the company private and simultaneously selling the RCM business. Morgan Keegan reported that that the 34% decline on Friday demonstrates a lack of confidence in the current strategy, as well as an unwillingness of...

Piper Jaffray, which downgraded shares of MedAssets, Inc. (NASDAQ: MDAS) – and lowered its PT from $21 to $15 – is providing some color on its 4Q results. “MDAS Q4 earnings missed on the top and bottom line, they guided below our street-low 2011 estimates, RCM backlog showed no growth,” Piper...